Last reviewed · How we verify
CFNB + Posterior Capsular Injection
CFNB + Posterior Capsular Injection is a Intracameral antimicrobial/anti-inflammatory combination Small molecule drug developed by University of Manitoba. It is currently FDA-approved for Prophylaxis of endophthalmitis in cataract surgery, Reduction of post-operative inflammation following cataract extraction.
CFNB (Cyclopentolate Fortified Neomycin B) with posterior capsular injection delivers antimicrobial and anti-inflammatory agents directly to the posterior segment of the eye during cataract surgery.
CFNB (Cyclopentolate Fortified Neomycin B) with posterior capsular injection delivers antimicrobial and anti-inflammatory agents directly to the posterior segment of the eye during cataract surgery. Used for Prophylaxis of endophthalmitis in cataract surgery, Reduction of post-operative inflammation following cataract extraction.
At a glance
| Generic name | CFNB + Posterior Capsular Injection |
|---|---|
| Sponsor | University of Manitoba |
| Drug class | Intracameral antimicrobial/anti-inflammatory combination |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This combination therapy involves intracameral or posterior capsular injection of a fortified antimicrobial formulation to prevent endophthalmitis and reduce inflammation following cataract surgery. The posterior capsular delivery route ensures high local concentrations at the site of surgical trauma while minimizing systemic exposure.
Approved indications
- Prophylaxis of endophthalmitis in cataract surgery
- Reduction of post-operative inflammation following cataract extraction
Common side effects
- Corneal edema
- Anterior chamber inflammation
- Transient vision disturbance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CFNB + Posterior Capsular Injection CI brief — competitive landscape report
- CFNB + Posterior Capsular Injection updates RSS · CI watch RSS
- University of Manitoba portfolio CI
Frequently asked questions about CFNB + Posterior Capsular Injection
What is CFNB + Posterior Capsular Injection?
How does CFNB + Posterior Capsular Injection work?
What is CFNB + Posterior Capsular Injection used for?
Who makes CFNB + Posterior Capsular Injection?
What drug class is CFNB + Posterior Capsular Injection in?
What development phase is CFNB + Posterior Capsular Injection in?
What are the side effects of CFNB + Posterior Capsular Injection?
Related
- Drug class: All Intracameral antimicrobial/anti-inflammatory combination drugs
- Manufacturer: University of Manitoba — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Prophylaxis of endophthalmitis in cataract surgery
- Indication: Drugs for Reduction of post-operative inflammation following cataract extraction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing